|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Prostate specific antigen (PSA) monitoring and histopathological examination of tumor biopsies remain gold standards in PCa diagnostics.
|
31577907 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The primary endpoint of confirmed response was defined as a composite of all patients presenting with any of the following outcomes: radiological objective response (as assessed by Response Evaluation Criteria in Solid Tumors 1.1), a decrease in prostate-specific antigen (PSA) of 50% or more (PSA50) from baseline, or conversion of circulating tumour cell count (from ≥5 cells per 7·5 mL blood at baseline to <5 cells per 7·5 mL blood).
|
31806540 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The pre-biopsy (bx) prostate-specific antigen (PSA) level, tumor volume/diameter, degree of extraprostatic extension (EPE), and extent of surgical margin positivity have been shown to be significant prognostic parameters of biochemical recurrence (BCR) after radical prostatectomy.
|
31837592 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Prostate-specific antigen (PSA) is the tumor marker most widely used in conjunction with digital rectal examination (DRE) for the early detection of prostate cancer (PCa).
|
31765638 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PSA and CTC reductions were associated with high PSMA expression (CTCs or tumor tissue) and low neuroendocrine serum markers.
|
31742767 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To study if prostatic ductal adenocarcinoma (PDA) controlled by Grade Group (GG), PSA, and tumor volume (TV) is an independent predictor of adverse radical prostatectomy (RP) outcomes.
|
31711982 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The PSA response to ADT was the lowest in patients with ISUP high-grade tumors.
|
31732768 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the prebiopsy group a positive circulating tumor cell score combined with prostate specific antigen predicted clinically significant prostate cancer (AUC 0.869).
|
31389764 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In multivariate analyses, the noninstitutional Pbx (odds ratio [OR] = 2.56; 95% confidence interval [CI]: 1.86-3.51; P < .001), tumor positive core numbers in Pbx (OR = 1.11; 95%CI: 1.04-1.19; P = .003), increased prostate specific antigen (PSA) density (OR = 3.59; 95%CI: 1.03-12.52, P = .045) and age (OR = 1.03; 95%CI: 1.00-1.05, P = .046) were independent clinical predictors of GGU in overall cohort whereas only increased PSA density (OR = 5.94; 95%CI: 1.28-27.50; P = .023) was independent predictor in institutional cohort.
|
31794085 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using the s.c. model, mice were monitored weekly for weight loss, tumor volume (TV) and serum PSA.
|
31767941 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It consists of doxorubicin (Dox) conjugated to a prostate specific antigen (PSA)-cleavable peptide that can be selectively activated by secreted PSA at the tumor site.
|
30802065 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Low risk inclusion criteria included PSA < 10 ng/ml, cT1c or cT2a, Grade Group (GG) 1, < 3 positive cores, and < 50% tumor in a single core with the majority having a PSA density of < 0.15.
|
31014300 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
There is still a need for a tumor marker with higher sensitivity and specificity than that of PSA.
|
31045265 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
For negative prebiopsy multiparametric magnetic resonance images a prostate specific antigen density cutoff of 0.15 ng/ml<sup>2</sup> or greater increased clinically significant prostate cancer detection only if the latter was defined as Gleason Grade Group 3-5 disease and/or tumor length 6 mm or greater.
|
30266332 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Area under the curve (AUC) analysis revealed that this combination was more accurate [AUC = 0.913 95% confidence interval (CI) 0.782-1] than a classical non-invasive selected clinical panel comprising age, tumor clinical stage (T-classification) and total serum PSA (AUC = 0.721 95% CI 0.613-0.830).
|
31500625 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status.
|
31537406 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Both SUVmax and SUVmean positively correlated with Gleason score (SUVmax Spearman r=0.546 p<0.01, SUVmean Spearman r=0.359 p<0.01), PSA level (SUVmax Spearman r=0.568 p<0.01, SUVmean Spearman r=0.529 p<0.01) and tumor volume (SUVmax Spearman r=0.635 p<0.01, SUVmean Spearman r=0.590 p<0.01).
|
31359744 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SARI protein expression did not correlate with the prostate cancer patients' age or serum Prostate-Specific Antigen value but did show a correlation with the tumor stage of prostate cancer and Gleason score.
|
31276688 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The median progression-free survival was 4.4 months with cabazitaxel and 2.7 months with an androgen-signaling-targeted inhibitor (hazard ratio for progression or death, 0.52; 95% CI, 0.40 to 0.68; P<0.001), a prostate-specific antigen response occurred in 35.7% and 13.5% of the patients, respectively (P<0.001), and tumor response was noted in 36.5% and 11.5% (P = 0.004).
|
31566937 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Of patient and tumor characteristics (PSA > 4 ng/mL, cT2a and > 1 positive core) only the proportion of NIT patients aged < 65 years increased over time from 47.3% to 53.2% (P = .03).
|
30342845 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Creating age-specific reference ranges could improve the sensitivity of the PSA tests by allowing the detection of treatable tumors in younger men if the threshold of 4.0 ng/mL is lowered.
|
30731465 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Conclusion A decrease in the serum PSA levels was observed after palliative TURP, and despite having received ADT, it was possible to determine tumor pathology in the resected tissue, being able to identify a greater grade group compared the GS at the time of diagnosis.
|
31723501 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Herein, we explored the transformation of the ML-peptide into an albumin-binding prodrug containing a tumor specific release mechanism based on the prostate-specific antigen.
|
30765725 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cox proportional hazards regression was utilized to relate FLT uptake and other clinical markers (PSA and tumor size) to progression-free survival.
|
30700328 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
GETUG-AFU 16 was an open-label, multicentre, phase 3, randomised, controlled trial that enrolled men (aged ≥18 years) with Eastern Cooperative Oncology Group performance status of 0 or 1, with histologically confirmed adenocarcinoma of the prostate (but no previous androgen suppression or pelvic radiotherapy), stage pT2, T3, or T4a (bladder neck involvement only) and pN0 or pNx according to the tumour, node, metastasis (TNM) staging system, whose prostate-specific antigen (PSA) concentration increased from 0·1 ng/mL to between 0·2 ng/mL and 2·0 ng/mL after radical prostatectomy, without evidence of clinical disease.
|
31629656 |
2019 |